Prognostic significance of VEGF expression in osteosarcoma: A meta-analysis

Tumor Biology

Volumn 35, Issue 1, 2014, Pages 155-160

  Yu, Xiao Wei ^a,b   Wu, Tian Yi ^a,b   Yi, Xiang ^b   Ren, Wei Ping ^c   Zhou, Zu Bin ^a   Sun, Yu Qiang ^a   Zhang, Chang Qing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c Wayne State University   (United States)

Author keywords

Meta analysis; Osteosarcoma; Prognosis; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ARTICLE; ASIAN; BIBLIOGRAPHIC DATABASE; CANCER PATIENT; CANCER PROGNOSIS; CARCINOGENESIS; CLINICAL EVALUATION; DISEASE SEVERITY; EMBASE; GENE OVEREXPRESSION; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); OSTEOSARCOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PUBLISHING; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RACE DIFFERENCE; SYSTEMATIC REVIEW;

BONE NEOPLASMS; GENE EXPRESSION; HUMANS; OSTEOSARCOMA; PROGNOSIS; PUBLICATION BIAS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84893731454     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1019-1     Document Type: Article

References (43)

1. Mirra JM, Gold RH, Picci P. Osseous tumors of intramedullary origin. In: Mirra JM, editor. Bone tumors: clinical radiologic, and pathologic correlations. Philadelphia: Lea and Febiger; 1989. p. 143-438.
2. Bielack S, Jürgens H, Jundt G, et al. Osteosarcoma: the COSS experience. Cancer Treat Res. 2010;152:289-308.
3. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteo-sarcoma: a critical review. J Clin Oncol. 1994;12:423-31.
4. Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemo-therapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;1:1154-61.
5. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2:795-803.
6. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011-27.
7. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ. 2001;323(7306):224-8.
8. Zhan P, Qian Q, Yu LK. Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Dis. 2013;5(1):40-7. doi: 10.3978/j.issn.2072-1439.2013.01.02.
9. Zhan P, Qian Q, Wan B, Yan TD, Yu LK. Prognostic value of TTF-1 expression in patients with non-small cell lung cancer: a meta-analysis. Transl Cancer Res. 2013;2(1):25-32. doi: 10.3978/j.issn.2218-676X.2013.02.08.
10. Zhan P, Wang Q, Qian Q, Yu LK. Megestrol acetate in cancer patients with anorexia-cachexia syndrome: a meta-analysis. Transl Cancer Res. 2013;2(2):74-9. doi: 10.3978/j.issn.2218-676X.2013.04.13.
11. Zhan P, Wang Q, Qian Q, Yu LK. Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials. Clin Oncol: Chin; 2013 Jan 03.
12. Zhan P, Qian Q, Yu LK. Prognostic significance of vascular endothelial growth factor expression in hepatocellular carcinoma tissue: a meta-analysis. Hepatobiliary Surg Nutr 2013 Jun 21. doi: 10.3978/j.issn.2304-3881.2013.06.06
13. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform metaanalyses of the published literature for survival endpoints. Stat Med. 1998;17:2815-34.
14. Yusuf S, Peto R, Lewis J, et al. Blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-71.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
16. Egger M, Smith GD, Schneider M. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
17. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-101.
18. Lee YH, Tokunaga T, Oshika Y, et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer. 1999;35(7):1089-93.
19. Handa A, Tokunaga T, Tsuchida T, et al. Neuropilin-2 expression affects the increased vascularization and is a prognostic factor in osteosarcoma. Int J Oncol. 2000;17(2):291-5.
20. Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000;6(2):572-7.
21. Jung ST, Moon ES, Seo HY, Kim JS, Kim GJ, Kim YK. Expression and significance of TGF-beta isoform and VEGF in osteosar-coma. Orthopedics. 2005;28(8):755-60.
22. Charity RM, Foukas AF, Deshmukh NS, Grimer RJ. Vascular endothelial growth factor expression in osteosarcoma. Clin Orthop Relat Res. 2006;448:193-8.
23. Ek ET, Ojaimi J, Kitagawa Y, Choong PF. Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma. Oncol Rep. 2006;16(1):17-23.
24. Oda Y, Yamamoto H, Tamiya S, et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol. 2006;19(5):738-45.
25. Abdeen A, Chou AJ, Healey JH, et al. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer. 2009;115(22):5243-50.
26. Kaya M, Wada T, Nagoya S, Sasaki M, Matsumura T, Yamashita T. The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma. J Bone Joint Surg Br. 2009;91(6):784-8.
27. Boulytcheva IV, Soloviev YN, Kushlinskii NE, Mahson AN. Expression of molecular markers in the tumor and survival prognosis in osteosarcoma. Bull Exp Biol Med. 2010;150(2):237-42.
28. Zhou Q, Zhu Y, Deng Z, Long H, Zhang S, Chen X. VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma. Surg Oncol. 2011;20(1):13-9.
29. Ługowska I, WoÅöniak W, Klepacka T, Michalak E, Szamotulska K. A prognostic evaluation of vascular endothelial growth factor in children and young adults with osteosarcoma. Pediatr Blood Cancer. 2011;15;57(1):63-8.
30. Chen Y, Wang CM, Shi YQ, Yang Y. Expression of hypoxia-inducible factor 1α in osteosarcoma and its value in predicting chemosensitivity [in Chinese]. Chien J Oncol. 2012;34(12):899-904.
31. Parikh AA, Ellis LM. The vascular endothelial growth factor family and its receptors. Hematol Oncol Clin North Am. 2004;18(5):951-71. vii.
32. Xie K, Wei D, Shi Q, Huang S. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev. 2004;15(5):297-324.
33. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011-27.
34. Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res. 2005;11(4):1434-40.
35. Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, Lin XQ, et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol. 2009;4(9):1094-103.
36. Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature Br J Cancer. 2006;94(12):1823-32.
37. Peng L, Zhan P, Zhou Y, Fang W, Zhao P, Zheng Y, et al. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Mol Biol Rep. 2012 Oct;39(10):9473-84.
38. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer. 2009;100(9):1385-92.
39. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res. 2006;12(17):5018-22.
40. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem. 2006;13(16):1845-57.
41. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-50.
42. Xu T, Chen J, Lu Y, Wolff JE. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. BMC Cancer. 2010;10:252.
43. Begg CB, Berlin JA. Publication bias: a problem in interpreting medical data. J R Stat Soc A. 1988;151:419-63.